Neuralink Rival Backed By Jeff Bezos And Bill Gates Broadens Horizons With Plans To Treat Parkinson's, Epilepsy
www.benzinga.com
May 10, 2024, 11:38 a.m.
On Thursday at the Bloomberg Tech Summit, Synchron’s founder, Tom Oxley, disclosed the company’s expansion strategy saying that it intends to adapt its existing device, the Stentrode, for these new treatments, reported Bloomberg. Oxley stated that the company intends to initiate a review by the U.S. Food and Drug Administration for its Parkinson's and epilepsy treatment, but refrained from specifying the timeline.